ROSAMERA

This brand name is authorized in Poland

Active ingredients

The drug ROSAMERA contains a combination of these active pharmaceutical ingredients (APIs):

1 Rosuvastatin
UNII 83MVU38M7Q - ROSUVASTATIN CALCIUM

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.

Read about Rosuvastatin
2 Amlodipine
UNII 1J444QC288 - AMLODIPINE

Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

Read about Amlodipine
3 Perindopril
UNII 1964X464OJ - PERINDOPRIL ERBUMINE

Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system).

Read about Perindopril

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C10BX14 C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BX Lipid modifying agents in combination with other drugs
Discover more medicines within C10BX14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: PL Rejestru Produktรณw Leczniczych Identifier(s): 100408063, 100408070, 100408086, 100408152, 100408169, 100408175

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.